

# Journal of Materials Chemistry B

Materials for biology and medicine

Accepted Manuscript

This article can be cited before page numbers have been issued, to do this please use: R. Foralosso, R. Kopyasz, G. Mantovani, S. Stolnik and C. Alexander, *J. Mater. Chem. B*, 2024, DOI: 10.1039/D3TB02102E.



This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.

# Synthetic macromolecular peptide-mimetics with amino acid substructure residues as protein stabilising excipients

View Article Online  
DOI: 10.1039/C3TB02102E

Ruggero Foralosso,<sup>a</sup> Rafał Jerzy Kopiasz,<sup>a,b</sup> Cameron Alexander,<sup>a,\*</sup> Giuseppe Mantovani<sup>a,\*</sup> and Snow Stolnik<sup>a,\*</sup>

<sup>a</sup>University of Nottingham, School of Pharmacy, NG7 2RD, UK

<sup>b</sup>Warsaw University of Technology, Faculty of Chemistry, Noakowskiego 3 St., 00-664, Warsaw, Poland

## Abstract

The clinical use of protein and peptide biotherapeutics requires fabrication of stable products. This particularly concerns stability towards aggregation of proteins or peptides. Here, we tested a hypothesis that interactions between a synthetic peptide, which is an aggregation-prone region analogue, and its homologous sequence on a protein of interest, could be exploited to design excipients which stabilise the protein against aggregation. A peptide containing the analogue of lysozyme aggregation-prone region (GILQINSRW) was conjugated to a RAFT agent and used to initiate the polymerisation of *N*-hydroxyethyl acrylamide, generating a GILQINSRW-HEA<sub>90</sub> polymer, which profoundly reduced lysozyme aggregation. Substitution of tryptophan in GILQINSRW with glycine, to form GILQINSRG, revealed that tryptophan is a critical amino acid in the protein stabilisation by GILQINSRW-HEA<sub>90</sub>. Accordingly, polymeric peptide-mimetics of tryptophan, phenylalanine and isoleucine, which are often present in aggregation-prone regions, were synthesized. These were based on synthetic oligomers of acrylamide derivatives of indole-3 acetic acid (IND), phenylacetic acid (PHEN), or 2-methyl butyric acid (MBA), respectively, conjugated with hydrophilic poly(*N*-hydroxyethyl acrylamide) blocks to form amphiphilic copolymers denoted as IND<sub>m</sub>-, PHEN<sub>m</sub>- and MTB<sub>m</sub>-*b*-HEA<sub>n</sub>. These materials were tested as protein stabilisers and it was shown that solution properties and the abilities of these materials to stabilise insulin and the peptide IDR 1018 towards aggregation are dependent on chemical nature of their side groups. These data suggest a structure-activity relationship, whereby indole-based IND<sub>m</sub>-*b*-HEA<sub>n</sub> peptide-mimetic displays properties of a potential stabilising excipient for protein formulations.

**Key words:** protein aggregation, protein stability, protein formulation, indole oligomers



## Introduction

The translation of proteins or peptides from biotechnology to biotherapeutic products offers potential treatments to a variety of diseases with unmet clinical need. The rationale for these biomolecules as therapeutics stems from their known mode of action, their inherent degradability as well as typical 'drug attributes' such as specificity and potency. This translation from an often complex and delicate macromolecule towards a medicine however requires fabrication of a stable product. This particularly concerns stability towards aggregation of protein or peptide molecules - the process by which unfolded molecules adopt a conformation that causes their clustering into aggregates or/and fibrils.<sup>1</sup> Hence, solutions are required to ensure stability to different stress factors during all stages of development and use of peptide or protein formulations. There are currently over 130 protein biotherapeutics in clinical practice, covering disease indications from diabetes, haemophilia, multiple sclerosis, hepatitis C and many cancers.<sup>2</sup> These employ a range of stabilising strategies, including: addition of low-molecular weight compounds like amino acids glycine, proline and histidine,<sup>3</sup> sugars like trehalose and sucrose, or polyols such as sorbitol. Covalent attachment of polyethylene glycol (PEG) to therapeutic proteins is another option which provides formulation stabilisation, and which can also impact positively on *in vivo* performance. PEGylated colony-stimulating factors, interferons, erythropoietin and mAbs<sup>4-6</sup> are biotherapeutic products that have already reached clinical application. An alternative strategy is a non-covalent PEGylation of a protein, for example as shown by the use of cholanic acid-PEG to increase the half-life of recombinant human growth hormone (rh-GH) and recombinant human granulocyte colony stimulating factor (rh-G-CSF) *in vivo*,<sup>7,8</sup> and tryptophan-PEG was used to reduce significantly the aggregation of salmon calcitonin *in vitro*.<sup>9</sup> In a related context, mPEG<sub>2k</sub>-poly(glutamic acid) copolymers have been utilised to form reversible protein complexes formulated for application to the lung.<sup>10</sup> Synthetic copolymers containing carbohydrate pendant units, especially trehalose-based, have also been used to reduce/modulate protein aggregation.<sup>11-14</sup>

The aggregation of many protein or peptide molecules can be attributed to the existence of 5-15 amino acid long regions that display high hydrophobicity, low net charge, and a high tendency to form  $\beta$ -structures. These are usually termed aggregation-prone regions (APR), and have been shown to be responsible for the aggregation of a range of proteins.<sup>15,16</sup> APRs are typically buried within a protein's hydrophobic core and/or positioned close to the active site of enzymes or polypeptide ligands,<sup>17,18</sup> and the aggregation process is normally initiated by their exposure to the solvent. Protein unfolding, caused by stress factors (e.g. temperature or pH), or intrinsic factors (e.g. destabilisation of the native structure by genetic mutation) can expose the amino acid sequence of the APR and initiate their self-assembly and



consequent protein aggregation. Disruption of APR self-assembly has thus been investigated as an approach to prevent the formation of amyloid aggregates by endogenous proteins, observed to occur in neurodegenerative diseases such as Alzheimer's.<sup>19</sup> It has been suggested that synthetic peptides, termed  $\beta$ -sheet breakers, could be developed to be capable of binding the amyloid precursor  $\alpha\beta$  fragment, but unable to self-assemble into a  $\beta$ -sheet structure.<sup>20</sup> Such peptides have been shown to prevent aggregation of the  $\alpha\beta$  peptide into amyloid fibrils *in vitro*.<sup>21–25</sup>

The starting premise of this study was that a stabilizing excipient could be designed comprising a peptide with an amino acid sequence analogous to that of APR, in order to bind strongly to an 'unfolding protein' on the path to aggregation, but with a hydrophilic chain conjugated to the peptide in order to provide a steric barrier towards protein aggregation. This approach might be considered analogous to bioconjugation and PEGylation strategies, but with an 'associative linker' rather than a conjugate, which interfered in the kinetics of aggregation by blocking access to an intermediate in the protein fragment self-association pathway. The protein lysozyme, and the peptide Gly-Ile-Leu-Gln-Ile-Asn-Ser-Arg-Trp (GILQINSRW) previously identified as the aggregation-prone region in lysozyme,<sup>26</sup> were selected as a model system. The GILQINSRW peptide was synthesized, incorporated into a RAFT chain-transfer agent (CTA), which was used to mediate the polymerisation of *N*-hydroxyethylacrylamide (HEA), forming the required hydrophilic block. Initial experiments identified the crucial role of tryptophan (Trp/W) amino acid of the GILQINSRW sequence in the stabilisation of lysozyme towards aggregation. We then further focused on the synthesis of a tryptophan peptide-mimetic based on indole - a side group of tryptophan, with the aim to test if such a synthetic material could achieve a stabilising effect comparable to that of tryptophan in a peptide or polymer sequence. Accordingly, RAFT CTAs incorporating indole oligomers were synthesised and used to mediate the polymerisation of HEA as a hydrophilic block. For comparison, and to assess if a structure-activity relationship could be established, we also synthesized peptide-mimetics of two other amino acids normally present in APRs, phenylalanine (Phe/F) and isoleucine (Ile/I) – based on phenylacetic acid, and methyl butyric acid structures, respectively. The resulting materials were compared for their ability to moderate the aggregation of insulin and the anti-microbial peptide, IDR 1018,<sup>27</sup> as representative therapeutic biomolecules, and promising initial activities of these materials were obtained.

## Results and discussion

### *Peptide-HEA conjugations synthesis*


To investigate the possibility for stabilising lysozyme with peptides analogue of its APR region, short peptide Gly-Ile-Leu-Gln-Ile-Asn-Ser-Arg-Trp (GILQINSRW, residues 54–62)<sup>26</sup> was



synthesised. Interestingly, Tokunaga *et al.* have shown that the GILQINSRW fragment of lysozyme APR self-assembles through mutual  $\beta$ -sheet interactions, but a single amino acid substitution of tryptophan with glycine (GILQINSRG) completely suppresses the aggregation.<sup>28</sup> Hence, to gain further insight to whether GILQINSRW peptide impacts on the aggregation of lysozyme *via* an interaction of its GILQINSRW sequences with APR, an analogous peptide Gly-Ile-Leu-Gln-Ile-Asn-Ser-Arg-Gly (GILQINSRG) was also synthesised. Both GILQINSRW and GILQINSRG peptides were prepared by solid-state peptide synthesis on 2-chlorotrityl chloride resin using Fmoc-protected amino acids (Figure 1a and Section 3 in SI). Additionally, to (i) circumvent water solubility issues and self-aggregation of the peptide itself,<sup>28</sup> and (ii) provide steric stabilisation against aggregation of the protein molecules once GILQINSRW and GILQINSRG were able to interact with lysozyme, the linkage of the peptides with a very hydrophilic polymer chain was carried out. In these cases, poly(*N*-hydroxyethyl acrylamide) (pHEA) and the peptide-polymer conjugates HEA<sub>90</sub>-GILQINSRW (**1**) and HEA<sub>95</sub>-GILQINSRG (**2**), were also obtained (Figure 1a). This process involved coupling of a 4-(((ethylthio)carbonothioyl)thio)-4-methylpentanoic, as a chain transfer agent (CTA), to the resin-bound peptides (**1a** and **2a**) and subsequent cleavage from the resin to obtain GILQINSRW- and GILQINSRG-RAFT agents **1b** and **2b** (Figure 1a). These agents were subsequently used to mediate the RAFT polymerisation of HEA, followed by cleavage of the amino acid protecting groups giving the final materials HEA<sub>90</sub>-GILQINSRW (**1**) and HEA<sub>95</sub>-GILQINSRG (**2**). The obtained polymer-peptide conjugates, as well as RAFT agents **1b** and **2b**, were characterised by <sup>1</sup>H NMR spectroscopy and HR-MS (Figure 1c and Figures S1-S11), which confirmed their structure and purity. Conjugates **1** and **2** were additionally characterised by size-exclusion chromatography (SEC) (Table 1). Additionally, poly(*N*-hydroxyethyl acrylamide) without additional functionalities (HEA<sub>100</sub>) was synthesised as control polymers as shown in Figure 1b (characterisation data in Table 1).

View Article Online  
DOI:10.1039/D3TB02102E





**Figure 1.** (a) Synthesis of HEA<sub>90</sub>-GILQINSRW, and HEA<sub>95</sub>-GILQINSRG; (b) synthesis of HEA<sub>n</sub> as control polymers; (c) <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) spectra of obtained GILQINSRW-HEA<sub>90</sub> conjugation. Reagents and conditions: a) DMF, DIPEA, rt; b) DMF, piperidine, rt; c) DMF, Fmoc-amino acid, HATU, DIPEA, rt; d) CTA, HATU, TEA, DMF, rt; e) DCM/TFE 8:2 v/v, rt; f) *N*-Hydroxyethyl acrylamide, V501, DMF, 70 °C; g) AIBN, DMF, 80 °C; h) 0.1 N HCl in hexafluoro-2-propanol (HFIP), rt.

**Table 1.** Composition,  $M_n$ , and dispersity of obtained peptides and polyHEA.

Composition	$M_{n,THEO}^a$ (kDa)	$M_{n,NMR}^b$ (kDa)	$M_{n,SEC}^c$ (kDa)	$\mathcal{D}$
HEA <sub>90</sub> -GILQINSRW (1)	10.5	10.8 <sup>b</sup>	17.0	1.09
HEA <sub>95</sub> -GILQINSRG (2)	10.3	12.1 <sup>b</sup>	14.8	1.13
HEA <sub>100</sub>	7.6	-	12.1	1.14


Composition is indicated by numbers in subscript. <sup>a</sup> Calculated from initial [HEA]:[CTA] and final monomer conversion; <sup>b</sup> number of repeating units of HEA calculated from <sup>1</sup>H NMR spectra by comparing the integral of peptides' methyl groups with the hydroxyl peak of HEA repeating units. <sup>c</sup> Obtained from SEC in DMF + 0.1% LiBr (PMMA standards).



### Moderation of lysozyme aggregation.

We tested the potential of HEA<sub>90</sub>-GILQINSRW to stabilize lysozyme in an alkaline medium which induces its aggregation. While the peptide GILQINSRW was insoluble in water, the polymer-peptide conjugate was freely soluble in both water and in phosphate buffer up to the highest tested concentration of 0.035 mg. mL<sup>-1</sup>. Accordingly, phosphate buffer was chosen as an appropriate medium for the lysozyme aggregation studies, in this case at a pH of 12.3 with assays conducted at room temperature, as these are conditions known to denature lysozyme.<sup>29,30</sup> This approach assumes that these conditions promote unfolding of the protein exposing its APR, which makes it more accessible to APR from other lysozyme protein molecules and to the APR-like sequence from HEA<sub>90</sub>-GILQINSRW.

The results of the lysozyme aggregation study are shown in Figure 2 and confirm the formation of large aggregates in control samples containing only lysozyme. Conversely, in the presence of HEA<sub>90</sub>-GILQINSRW (1:1 mol with respect to lysozyme) the onset of aggregation was delayed by 10 hours, and within 24 hours of the experiment the aggregation remains relatively low. The profiles further indicated an increased rate of aggregation in the presence of the HEA<sub>100</sub> homopolymer, which is analogous to HEA<sub>90</sub>-GILQINSRW but lacks the GILQINSRW peptide block. This may be ascribed to the macromolecular crowding induced by the simultaneous presence in solution of two macromolecules, the protein and the polymer, at relatively high concentration (10 mg/mL lysozyme, 9 mg/mL HEA<sub>100</sub>) and the 'excluded volume' occupied by the polymer increasing the chances of protein-protein interaction and precipitation.<sup>29,30</sup> The aggregation profile of HEA<sub>95</sub>-GILQINSRG shows that it does not modulate lysozyme aggregation. On the contrary, it appears that HEA<sub>95</sub>-GILQINSRG causes an increase in the rate of aggregation, similar to the control polymer HEA<sub>100</sub>, further indicating the absence of associative interactions with the protein-aggregation region.



**Figure 2.** Aggregation assay for lysozyme (10 mg/mL) in the presence of HEA<sub>90</sub>-GILQINSRW, HEA<sub>95</sub>-GILQINSRG, and HEA<sub>100</sub> in 100 mM phosphate buffer pH 12.3; molar ratio of peptides and HEA<sub>100</sub> to lysozyme was 1:1. Lysozyme aggregation assessed by turbidimetry at  $\lambda=500$  nm, readings were taken every 30 min for 24 h.



These data indicate that the modification of a single amino acid in the peptide sequence from GILQINSRW to GILQINSRG suppresses interaction of the corresponding HEA<sub>95</sub>-GILQINSRG conjugate with lysozyme, in line with the reported loss of self-aggregation of the GILQINSRW peptide when its terminal W is replaced with G residue.<sup>28</sup> This suggests that the stabilisation effect of HEA<sub>90</sub>-GILQINSRW may be attributed to the specific interaction between its GILQINSRW moiety and the homologous aggregation-prone region on lysozyme. The results further highlight the decisive role of tryptophan to maintain anti-aggregation properties of the GILQINSRW sequence.


### **Synthesis of copolymeric peptide-mimetics**

After identifying the key role of tryptophan in the HEA<sub>90</sub>-GILQINSRW stabilisation of lysozyme (Figure 2), we synthesised tryptophan peptide-mimetic block copolymers based on indole-3 acetic acid (Figure 3a), acknowledging that the pendant indole group defines many physico-chemical properties of tryptophan.<sup>31</sup> As other hydrophobic amino acids, like phenylalanine and isoleucine, play an important role in the protein aggregation process and are abundant in ARPs of many proteins, our studies on peptide mimetics were extended to include block copolymers containing phenyl and *iso*-butyl groups, as mimics of the side chains of these amino acids (Figure 3a).

As the first step, acrylic monomers IND, PHEN, and MTB were obtained via coupling of *N*-hydroxyethyl acrylamide with indole-3 acetic acid, phenylacetic acid, and methylbutyric acid, respectively (Scheme S3, Section 5.1 in the supporting information). Then, these monomers were polymerised by RAFT polymerisation, to synthesise hydrophobic oligomeric chain transfer agents (CTAs) IND<sub>*m*</sub>, PHEN<sub>*m*</sub>, and MTB<sub>*m*</sub> (*m* = 1, 3, 10, Figure 3a and Section 5.2 in SI). Purification of the oligomeric CTAs with *m* = 1 and *m* = 3 was carried out by flash chromatography, in analogy with the purification of discrete oligomers on silica described by Hawker and co-workers,<sup>32</sup> whereas CTAs with average *m* = 10 were used as obtained from the RAFT reaction, without the additional chromatographic step.







**Figure 3.** (a) Synthesis of  $\text{IND}_m^-$ ,  $\text{PHEN}_m^-$ ,  $\text{MTB}_m^-$ - $b$ - $\text{HEA}_n$  block copolymers. *Reagents and conditions:* a) AIBN, CTA, DMF, 80 °C; b) *N*-hydroxyethyl acrylamide, V501, DMF, 70 °C; (b)  $^1\text{H}$  NMR (DMSO- $d_6$ , 400 MHz) spectrum of  $\text{IND}_3$ - $\text{HEA}_{95}$  as a representative spectrum of the synthesised block copolymers; SEC chromatograms of  $\text{IND}_m^-$ - $b$ - $\text{HEA}_n$  copolymers with (c) shorter and (d) longer hydrophilic blocks, using DMF with 0.1% LiBr as the mobile phase. Spectra and SEC chromatograms of all polymers are shown in Sections 5.3.1 and 5.3.2 in the supporting information.



Subsequently, the oligomeric CTAs were used to mediate the RAFT polymerisation of *N*-hydroxyethyl acrylamide, aiming at degrees of polymerisation (DP) of 40 and 100, to investigate the influence of the size of the polyHEA block on protein-copolymer interaction. The resulting block copolymers  $\text{IND}_m\text{-}b\text{-HEA}_n$ ,  $\text{PHEN}_m\text{-}b\text{-HEA}_n$ ,  $\text{MTB}_m\text{-}b\text{-HEA}_n$  were characterised using  $^1\text{H}$  NMR spectroscopy and SEC (Figure 3 b-d, Table 2, and Section 5.3 in the supporting information). A small shoulder at higher molar masses was observed in the SEC traces of  $\text{IND}_n\text{-}b\text{-HEA}_m$  block copolymers, which may be ascribable to a small extent of bimolecular coupling termination, which can occur in RAFT polymerisation.<sup>33</sup> The discrepancy between number average molar mass determined by  $^1\text{H}$  NMR ( $M_{n,\text{NMR}}$ ) and SEC ( $M_{n,\text{SEC}}$ ) may result from differences in polymer hydrodynamic volume compared to the standards employed for calibration of SEC.

**Table 2.**  $M_n$  and dispersity of  $\text{IND}_m\text{-}$ ,  $\text{PHEN}_m\text{-}$ ,  $\text{MTB}_m\text{-}b\text{-HEA}_n$  materials synthesised in this work.


Composition	$M_{n,\text{THEO}}^a$ (kDa)	$M_{n,\text{NMR}}$ (kDa)	$M_{n,\text{SEC}}^e$ (kDa)	$\mathcal{D}$	Composition	$M_{n,\text{THEO}}^a$ (kDa)	$M_{n,\text{NMR}}$ (kDa)	$M_{n,\text{SEC}}^e$ (kDa)	$\mathcal{D}$
$\text{IND}_1\text{-}b\text{-HEA}_{37}$	5.5	5.0 <sup>b</sup>	8.7	1.07	$\text{IND}_1\text{-}b\text{-HEA}_{100}$	9.0	8.7 <sup>b</sup>	13	1.08
$\text{PHEN}_1\text{-}b\text{-HEA}_{37}$	5.1	4.8 <sup>c</sup>	9.0	1.07	$\text{PHEN}_1\text{-}b\text{-HEA}_{100}$	12	12.2 <sup>c</sup>	18.6	1.08
$\text{MTB}_1\text{-}b\text{-HEA}_{37}$	5.9	4.8 <sup>d</sup>	10.4	1.05	$\text{MTB}_1\text{-}b\text{-HEA}_{111}$	13.1	13.2 <sup>d</sup>	19.8	1.09
$\text{IND}_3\text{-}b\text{-HEA}_{53}$	5.4	6.7 <sup>b</sup>	11.7	1.09	$\text{IND}_3\text{-}b\text{-HEA}_{98}$	11.5	12 <sup>b</sup>	17	1.11
$\text{PHEN}_3\text{-}b\text{-HEA}_{45}$	5.4	6.2 <sup>c</sup>	9.6	1.07	$\text{PHEN}_3\text{-}b\text{-HEA}_{99}$	11.7	12.5 <sup>c</sup>	17.5	1.06
$\text{MTB}_3\text{-}b\text{-HEA}_{42}$	6.4	7.3 <sup>d</sup>	10.9	1.05	$\text{MTB}_3\text{-}b\text{-HEA}_{82}$	10.2	10.5 <sup>d</sup>	16.8	1.07
$\text{IND}_{10}\text{-}b\text{-HEA}_{40}$	6.1	7.7 <sup>b</sup>	10.5	1.15	$\text{IND}_{10}\text{-}b\text{-HEA}_{95}$	10.7	14.1 <sup>b</sup>	18.4	1.11
$\text{PHEN}_{10}\text{-}b\text{-HEA}_{38}$	6.8	7.0 <sup>c</sup>	10.7	1.08	$\text{PHEN}_{10}\text{-}b\text{-HEA}_{88}$	12.6	12.9 <sup>c</sup>	17.4	1.07
$\text{MTB}_{10}\text{-}b\text{-HEA}_{43}$	6.7	7.2 <sup>d</sup>	10.0	1.07	$\text{MTB}_{10}\text{-}b\text{-HEA}_{105}$	12.5	15.0 <sup>d</sup>	18.7	1.07
$\text{HEA}_{36}$	4.5		8.5	1.04	$\text{HEA}_{100}$	13		12.1	1.14

<sup>a</sup> Calculated from initial [HEA]:[CTA] and final monomer conversion; <sup>b-d</sup> Number of repeating units of HEA monomers calculated by  $^1\text{H}$  NMR, in  $\text{DMSO-d}_6$ , by comparing the integral of <sup>b</sup> indole aromatic, <sup>c</sup> methylene, or <sup>d</sup> methylbutyryl methyl peaks with the hydroxyl peak of HEA repeating units. <sup>e</sup> Obtained from SEC in DMF + 0.1% LiBr (PMMA standards).

### Characterisation of block copolymer self-assemblies

The synthesised  $\text{IND}_m\text{-}$ ,  $\text{PHEN}_m\text{-}$ , and  $\text{MTB}_m\text{-}b\text{-HEA}_n$  copolymers are amphiphilic molecules consisting of a hydrophobic and a hydrophilic block. Therefore, to further characterise them, their ability to self-assemble in aqueous environment was investigated by dynamic light scattering (Figure 4 and Table 3).





**Figure 4.** Size distribution (Volume %) of copolymers' self-assemblies (1 mg/mL) in DI water as determined by DLS.


**Table 3.** Hydrodynamic diameter measured by DLS of  $\text{IND}_m$ -,  $\text{PHEN}_m$ -, and  $\text{MTB}_m$ - $b$ - $\text{HEA}_n$  copolymers reported from volume distribution. Polydispersity indices are provided in brackets; materials were analysed at 1.0 mg/mL in DI water.

<b>Polymer:</b>	$\text{IND}_1$ - $b$ - $\text{HEA}_{37}$	$\text{PHEN}_1$ - $b$ - $\text{HEA}_{37}$	$\text{MTB}_1$ - $b$ - $\text{HEA}_{37}$	$\text{IND}_1$ - $b$ - $\text{HEA}_{100}$	$\text{PHEN}_1$ - $b$ - $\text{HEA}_{100}$	$\text{MTB}_1$ - $b$ - $\text{HEA}_{111}$
<b>Size (PDI) nm</b>	4.43 (0.26)	3.28 (0.62)	3.15 (0.36)	6.05 (0.11)	5.69 (0.05)	6.81 (0.43)
<b>Polymer:</b>	$\text{IND}_3$ - $b$ - $\text{HEA}_{53}$	$\text{MTB}_3$ - $b$ - $\text{HEA}_{42}$	$\text{MTB}_3$ - $b$ - $\text{HEA}_{42}$	$\text{IND}_3$ - $b$ - $\text{HEA}_{98}$	$\text{PHEN}_3$ - $b$ - $\text{HEA}_{99}$	$\text{MTB}_3$ - $b$ - $\text{HEA}_{82}$
<b>Size (PDI) nm</b>	5.54 (0.18)	3.53 (0.07)	4.73 (1.62)	5.21 (0.27)	6.23 (0.86)	5.40 (1.0)
<b>Polymer:</b>	$\text{IND}_{10}$ - $b$ - $\text{HEA}_{40}$	$\text{PHEN}_{10}$ - $b$ - $\text{HEA}_{38}$	$\text{MTB}_{10}$ - $b$ - $\text{HEA}_{43}$	$\text{IND}_{10}$ - $b$ - $\text{HEA}_{95}$	$\text{PHEN}_{10}$ - $b$ - $\text{HEA}_{88}$	$\text{MTB}_{10}$ - $b$ - $\text{HEA}_{105}$
<b>Size (PDI) nm</b>	9.73 (0.16)	9.71 (0.18)	6.54 (0.20)	14.28 (0.15)	12.03 (0.16)	5.38 (0.33)

Data for  $\text{IND}_m$ -,  $\text{PHEN}_m$ - and  $\text{MTB}_m$ - $\text{HEA}_n$  with  $m=1$  and 3 show average hydrodynamic particle diameters  $D_h$  of around 3-5 nm for shorter  $\text{HEA}_n$  ( $n \approx 37$ ), and of around 5-7 nm for longer  $\text{HEA}_n$  ( $n \approx 100$ ), with polydispersity indices representative of a relatively narrow particles size distribution. This is consistent with the presence of highly hydrated individual chains of these copolymers in a solvated extended conformation. For instance, the gyration radius of free PEG with molecular mass within the range of 2 kDa to 15 kDa ranging from 1.3 nm to 4 nm.<sup>34,35</sup> However,  $\text{IND}_{10}$ - and  $\text{PHEN}_{10}$ - $b$ - $\text{HEA}_n$  show significantly higher hydrodynamic diameters of around 10 nm for shorter  $\text{HEA}_n$  ( $n \approx 40$ ), and 12-14 nm for longer  $\text{HEA}_n$  ( $n \approx 100$ ). Interestingly, there is no measurable increase in diameter of  $\text{MTB}_{10}$ - $b$ - $\text{HEA}_n$  for either  $n=43$  or 105 in comparison with  $\text{MTB}_1$ - and  $\text{MTB}_3$ -. Taken together, these data indicate minimal or no aggregation in water of copolymers with  $m=1$  and 3, whilst a prolongation of the hydrophobic block content to 10 repeating units for indole- and phenyl-containing materials induces self-association into species of about 10-14 nm in size, with relatively narrow size distributions, as indicated by their PDI values. A possible explanation for this observation is an intermolecular interaction between aromatic indole and phenyl rings (e.g.  $\pi$ -stacking), which is not present in the case of the branched aliphatic methyl butyryl residues of  $\text{MTB}_m$ - $b$ - $\text{HEA}_n$  copolymers.



Further analysis of self-assembly behaviour of  $\text{IND}_{3^{-}}$  and  $\text{IND}_{10^{-}b}\text{-HEA}_n$  molecules in water by surface tension ( $\gamma$ ) measurements indicates that the former copolymer is a weak whereas the latter a strong surfactant, reducing  $\gamma$  to 66 mN/m and 58 mN/m, respectively (Figure 5). The  $\gamma$  vs. concentration plot for  $\text{IND}_{10^{-}b}\text{-HEA}_n$  presents a formation of supramolecular aggregates at a concentration between 1.0 and 2.0 mg/mL (critical aggregation concentration, CAC). In the case of  $\text{IND}_{3^{-}b}\text{-HEA}_{98}$ , the  $\gamma$  vs. concentration plot has no clear discontinuity or plateau at higher concentrations. This result agrees with our DLS analysis results (Table 3) that indicate an absence of self-assembled species for  $\text{IND}_{3^{-}b}\text{-HEA}_{98}$ .



**Figure 5.** Surface tension measurements of representative copolymers  $\text{IND}_{3^{-}b}\text{-HEA}_{98}$  and  $\text{IND}_{10^{-}b}\text{-HEA}_{95}$  carried out in water by pendant drop method.<sup>36</sup>


### Modulation of insulin aggregation by block copolymers

After identifying the key role of tryptophan in the  $\text{HEA}_{90}\text{-GILQINSRW}$  stabilisation of lysozyme, we studied tryptophan peptide-mimetic oligomers based on indole-3 acetic acid ( $\text{IND}_m\text{-b-HEA}_n$ ), on the basis that the indole ring contributes the defining physicochemical properties of tryptophan.<sup>31</sup> Unfortunately, under the alkaline conditions that induce lysozyme aggregation,  $\text{IND}_m\text{-}$ ,  $\text{PHEN}_m\text{-}$  and  $\text{MTB}_m\text{-b-HEA}_n$  materials failed to show any stabilizing effect (Figure S32 and S33, Section 6 in SI). Further analysis revealed that these aggregation favouring conditions (pH 12.3) induce hydrolysis of the ester groups linking the pendant indole group to the polymer backbone; the  $^1\text{H}$  NMR spectrum of  $\text{IND}_{10^{-}b}\text{-HEA}$  after incubation under such conditions displayed no indole aromatic protons peaks between 6.9 – 7.3 ppm (Spectrum S34, Section 6 in the supporting information).

Accordingly, we selected insulin as a model protein to replace lysozyme in the aggregations studies as it is well-established that the aggregation of insulin is initiated at pH around 5.3, corresponding to the protein isoelectric point.<sup>37</sup> The residues of insulin B-chain including GB8, SB9, VB12, EB13, YB16, GB23, FB24, FB25, YB26, and TB27 are believed to play an important role in insulin self-assembly.<sup>38</sup> The impact of the peptide-mimetic materials synthesized in this work on the aggregation of insulin is shown in Figure 6. Only 17% of insulin (0.34 mg/mL out



of 2 mg/mL) remained in a solution after incubation at conditions inducing its aggregation. However, the addition of  $\text{IND}_3$ - and  $\text{IND}_{10}$ -*b*- $\text{HEA}_m$  polymers at polymer:peptide molar ratio of 10 prevented aggregation very efficiently - almost 100% of insulin remained in its non-aggregated state after 20 h. Conversely, this effect was not observed for  $\text{IND}_1$ -*b*- $\text{HEA}_n$  which possesses only one indole group. For  $\text{PHEN}_m$ -based copolymers, only the longest copolymer,  $\text{PHEN}_{10}$ -*b*- $\text{HEA}_{88}$ , reduces aggregation (61% non-aggregated insulin retained), when compared to  $\text{HEA}_{100}$  control polymers (only 24% of residual insulin in solution). No measurable impact against insulin aggregation is seen for copolymers containing isoleucine-mimicking groups -  $\text{MTB}_m$ -*b*- $\text{HEA}_n$ .



**Figure 6. Insulin aggregation in the presence of  $\text{IND}_m$ -,  $\text{PHEN}_m$ - and  $\text{MTB}_m$ -*b*- $\text{HEA}_n$  materials.** Concentration of insulin remaining in a solution after incubation in the aggregation inducing conditions (pH 5.2) for 20 h without and with synthesised copolymers at different molar ratio; the initial concentration of insulin was 2 mg/mL. Higher values in the graph correspond to better protein stabilisation and hence reduced aggregation.

### Interaction of peptide-mimetic oligomers with insulin.

In the next step potential effects of the  $\text{IND}_{10}$ -based oligomers on the secondary structure of insulin were assessed by circular dichroism (CD). The analysis of samples in the presence of  $\text{IND}_{10}$ -*b*- $\text{HEA}_{95}$  produced poor signal-to-noise ratio, likely due to the presence of indole groups, as reported previously.<sup>39</sup> The analysis hence measured the CD profile after separation of insulin and  $\text{IND}_{10}$ -*b*- $\text{HEA}_{95}$ . Whilst this experiment cannot inform directly on secondary structure alterations that may be occurring during insulin interactions with stabilizing  $\text{IND}_{10}$ -*b*- $\text{HEA}_{95}$ , it however provides an insight to whether these interactions induce irreversible changes of the protein secondary structure (Figure S31). The profile obtained from the 'native' insulin, i.e. before any manipulation, exhibits two negative peaks, at 208 nm and 222




nm, as previously described for bovine insulin, and is typical of an  $\alpha$ -helix secondary structure.<sup>40</sup> A similar profile is seen for the sample subjected to HPLC purification. The two samples taken from insulin aggregation experiments in the presence of IND<sub>10</sub>-*b*-HEA<sub>95</sub> at 10:1 and 5:1 insulin molar ratios also show  $[\theta]$  vs. wavelength profiles similar to that of native insulin. The experiment hence indicates that the stabilizing IND<sub>10</sub>-*b*-HEA<sub>95</sub> peptide-mimetic does not cause irreversible changes in the protein secondary structure.

View Article Online  
DOI: 10.1039/B3TB02102E

### Moderation of IDR 1018 aggregation by block copolymers

To exemplify the potential of our synthetic peptide-mimetic materials to moderate aggregation of peptides, the IDR 1018 peptide, consisting of the amino acid sequence VRLIVAVRIWRR was selected. This peptide has been reported to show antimicrobial and immunomodulatory activities,<sup>41–43</sup> but clinical applications have been hampered by its tendency to aggregation under aqueous conditions. This aggregation has been attributed to the 5 consecutive hydrophobic residues between L3 and V7, which are believed to form the peptide's aggregation-prone region. The effect of IND<sub>*m*</sub><sup>-</sup>, PHEN<sub>*m*</sub><sup>-</sup>, and MTB<sub>*m*</sub>-*b*-HEA<sub>*n*</sub> materials on aggregation of the peptide was investigated in 100 mM pH 7.2 phosphate buffer, where IDR 1018 is known to aggregate,<sup>44</sup> and the results are presented in Figure 7.



**Figure 7.** The concentration of IDR 1018 remaining in a solution after incubation in aggregation conditions (100 mM phosphate buffer, pH 7.2) for 5 h without and with synthesised copolymers at 1:1 molar ratio; the initial concentration of the peptide was 0.153 mg/mL. Higher values in the graph correspond to better protein stabilisation and hence reduced aggregation.

Incubation of IDR 1018 in 100 mM phosphate buffer, pH 7.2 for 5 hours resulted in 75% peptide aggregation – 38.3 mg/mL final concentration from an initial 153 mg/L. However, in the presence of indole-based materials (IND<sub>3</sub>-*b*-HEA<sub>53</sub>, IND<sub>10</sub>-*b*-HEA<sub>40</sub>, IND<sub>3</sub>-*b*-HEA<sub>98</sub> and



IND<sub>10</sub>-*b*-HEA<sub>95</sub>) in a 1:1 (co)polymer: IDR 1018 molar ratio, as much as 70 – 80% of the peptide remained in solution under identical conditions, whereas for phenyl-based materials (PHEN<sub>10</sub>-*b*-HEA<sub>38</sub> and PHEN<sub>10</sub>-*b*-HEA<sub>100</sub>) it was around 50 – 75%. The other copolymers tested did not show any stabilization effect on IDR 1018 (Figure 7).

Data on behaviour of IND<sub>10</sub>- and PHEN<sub>10</sub>-*b*-HEA<sub>n</sub> copolymers in aqueous solutions (Table 3 and Figures 4 and 5), together with protein aggregation results (Figures 6 and 7), could be explained with the existence of an equilibrium between polymer self-assemblies and their interactions with the proteins and peptides tested, leading to their stabilization towards aggregation. This is apparent for IND<sub>10</sub>-HEA<sub>n</sub> and PHEN<sub>10</sub>-*b*-HEA<sub>n</sub> materials. Interestingly, similar protein stabilization induced by IND<sub>3</sub>-*b*-HEA<sub>n</sub> and IND<sub>10</sub>-*b*-HEA<sub>n</sub> may suggest that polymer self-assembly does not hamper interactions with proteins, as the former one does not self-assemble (Figure 5).

Collectively, the data indicate different impacts of copolymers bearing indole, phenyl, or methyl butyric side groups mimicking W, F, and I, respectively, on protein stabilisation. This observation may be ascribed to the physicochemical properties of tryptophan, strongly affected by its indole ring, observed via the influence of tryptophan on protein folding, as well as its positioning in lipid bilayers and in the membrane-spanning regions of transmembrane proteins. Tryptophan has a number of unique molecular features:<sup>45</sup> the largest nonpolar (hydrophobic) area of all amino acids due to the two-sided  $\pi$ -electron face of its indole side chain that is also polarizable and highly accessible because of its planar topology, the strongest electrostatic potential for cation- $\pi$  interactions, and an indole hydrogen-bond donor N-H moiety. The single phenyl ring, present in phenylalanine and PHEN<sub>m</sub>-*b*-HEA<sub>n</sub> copolymers, nor the short branched alkyl group present in isoleucine and MTB<sub>m</sub>-*b*-HEA<sub>n</sub>, do not exhibit the full range of these properties, hence their interactions with protein regions involved with the aggregation of the proteins and peptide tested may be limited. Furthermore, the presented data indicate to exert a protein stabilizing activity IND<sub>m</sub>-*b*-HEA<sub>n</sub> copolymers must comprise more than one indole-containing repeating unit (IND), as a tryptophan mimetic unit. Intriguingly, a PEG<sub>2k</sub>-tryptophan conjugate reported by Mueller et al.<sup>46</sup> has shown a significant stabilization effect on salmon calcitonin despite bearing only a single tryptophan unit, thus indicating that that the structure of tryptophan-containing stabilisers may need fine-tuning to achieve the desired protein/peptide stabilisation effect. Importantly, the proteins and peptides tested to date with tryptophan-containing stabilisers - lysozyme, insulin, IDR 1018, and salmon calcitonin – possess chemically distinct aggregation-prone regions (APRs), which underlines the versatility of indole moiety in protein stabilization.

## Conclusions

This work started with a hypothesis that interactions could be exploited between a synthetic peptide, which is an aggregation-prone region analogue, and its homologous sequence on a



protein, to design excipients to stabilise the protein against aggregation. The hypothesis further suggested that attachment of a hydrophilic polymer to such a peptide will provide a stabilisation effect, such that the associative interactions at the aggregation-prone region of the peptide mimetic with the protein would prevent full aggregation by the steric demands of the attached hydrophilic polymer. The synthesized GILQINSRW-HEA<sub>90</sub> polymer containing the lysozyme aggregation-prone region analogue indeed shows a dramatic reduction in lysozyme aggregation. Substitution of tryptophan in GILQINSRW with glycine to form GILQINSRG showed, via the lack of activity of the mutated peptide, that tryptophan was a decisive factor in the protein stabilisation by GILQINSRW-*b*-HEA<sub>90</sub>. This led to the successful synthesis of peptide-mimetics from tryptophan, phenylalanine and isoleucine amino acid analogues, based on synthetic oligomers of indole-3 acetic acid, phenylacetic acid, or methylbutyric acid, and with a block of poly(HEA) to provide aqueous solubility and steric stabilisation: IND<sub>m</sub>-, PHEN<sub>m</sub>- and MTB<sub>m</sub>-*b*-HEA<sub>n</sub>. The study then demonstrates that the solution properties and their ability of these materials to stabilise insulin and IDR 1018 peptide towards aggregation are dependent on the chemical nature of their side groups - indole vs phenyl vs methylbutyrate – with indole based IND<sub>m</sub>-*b*-HEA<sub>n</sub> peptide-mimetic material displaying properties of a potential stabilising excipient to protein formulations.

View Article Online  
DOI: 10.1039/D3TB02102E

## Experimental section

For materials, synthetic procedures and analytical methods see the supporting information.

## Author Contributions

Ruggero Foralosso – investigation, methodology, formal analysis. Rafal Kopiasz – formal analysis, writing-original draft, writing- review and editing. Giuseppe Mantovani- supervision, writing- review and editing. Cameron Alexander, funding acquisition, supervision, writing- review and editing. Snow Stolnik, funding acquisition, supervision, writing- review and editing.

## Conflict of interest

There are no conflicts to declare.

## Acknowledgements

This work was funded by the Engineering and Physical Science Research Council [EP/L01646X/1] and the Royal Society [Wolfson Research Merit Award WM150086 to CA]. We thank Dr Marco di Antonio (University of Cambridge) for conducting the circular





dichroism experiments. We also thank Tom Hyde, Esme Ireson and Paul Cooling for expert technical support.

View Article Online  
DOI: 10.1039/D3TB02102E

## Data access statement

All relevant data can be obtained upon request from the authors at [giuseppe.mantovani@nottingham.ac.uk](mailto:giuseppe.mantovani@nottingham.ac.uk), [snow.stolnik@nottingham.ac.uk](mailto:snow.stolnik@nottingham.ac.uk) and [cameron.alexander@nottingham.ac.uk](mailto:cameron.alexander@nottingham.ac.uk)

## References

- 1 M. Stefani, *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease*, 2004, **1739**, 5–25.
- 2 M. Evans, P. M. Schumm-Draeger, J. Vora and A. B. King, *Diabetes Obes Metab*, 2011, **13**, 677–684.
- 3 S. Saurabh, C. Kalonia, Z. Li, P. Hollowell, T. Waigh, P. Li, J. Webster, J. M. Seddon, J. R. Lu and F. Bresme, *Mol Pharm*, 2022, **19**, 3288–3303.
- 4 M. J. Roberts, M. D. Bentley and J. M. Harris, *Adv Drug Deliv Rev*, 2002, **54**, 459–476.
- 5 P. L. Turecek, M. J. Bossard, F. Schoetens and I. A. Ivens, *J Pharm Sci*, 2016, **105**, 460–475.
- 6 F. M. Veronese and G. Pasut, *Drug Discov Today*, 2005, **10**, 1451–1458.
- 7 S. Salmaso, S. Bersani, F. Mastrotto, G. Tonon, R. Schrepfer, S. Genovese and P. Caliceti, *Journal of Controlled Release*, 2012, **162**, 176–184.
- 8 S. Salmaso, S. Bersani, A. Scomparin, A. Balasso, C. Brazzale, M. Barattin and P. Caliceti, *Journal of Controlled Release*, 2014, **194**, 168–177.
- 9 C. Mueller, M. A. H. Capelle, E. Seyrek, S. Martel, P.-A. Carrupt, T. Arvinte and G. Borchard, *J Pharm Sci*, 2012, **101**, 1995–2008.
- 10 A. Nieto-Orellana, M. Di Antonio, C. Conte, F. H. Falcone, C. Bosquillon, N. Childerhouse, G. Mantovani and S. Stolnik, *Polym Chem*, 2017, **8**, 2210–2220.
- 11 R. J. Mancini, J. Lee and H. D. Maynard, *J Am Chem Soc*, 2012, **134**, 8474–8479.
- 12 J. Madeira do O, F. Mastrotto, N. Francini, S. Allen, C. F. van der Walle, S. Stolnik and G. Mantovani, *J Mater Chem B*, 2018, **6**, 1044–1054.
- 13 M. Milewska, A. Milewski, I. Wandzik and M. H. Stenzel, *Polym Chem*, 2022, **13**, 1831–1843.
- 14 A. N. Bristol, J. Saha, H. E. George, P. K. Das, L. K. Kemp, W. L. Jarrett, V. Rangachari and S. E. Morgan, *Biomacromolecules*, 2020, **21**, 4280–4293.
- 15 J. Beerten, J. Schymkowitz and F. Rousseau, *Curr Top Med Chem*, 2013, **12**, 2470–2478.
- 16 W. Wang and C. J. Roberts, Eds., *Aggregation of Therapeutic Proteins*, John Willey & Sons, Inc., New Jersey, 2010.
- 17 G. De Baets, J. Schymkowitz and F. Rousseau, *Essays Biochem*, 2014, **56**, 41–52.



- 18 A.-M. Fernandez-Escamilla, F. Rousseau, J. Schymkowitz and L. Serrano, *Nat Biotechnol*, 2004, **22**, 1302–1306. Article Online  
DOI: 10.1039/D3TB02102E
- 19 A. Aguzzi and T. O'Connor, *Nat Rev Drug Discov*, 2010, **9**, 237–248.
- 20 S. C. Li, N. K. Goto, K. A. Williams and C. M. Deber, *Proceedings of the National Academy of Sciences*, 1996, **93**, 6676–6681.
- 21 C. Soto, M. S. Kindy, M. Baumann and B. Frangione, *Biochem Biophys Res Commun*, 1996, **226**, 672–680.
- 22 C. Soto, E. M. Sigurdsson, L. Morelli, R. Asok Kumar, E. M. Castaño and B. Frangione, *Nat Med*, 1998, **4**, 822–826.
- 23 C. Adessi and C. Soto, *Drug Dev Res*, 2002, **56**, 184–193.
- 24 L. O. Tjernberg, D. J. E. Callaway, A. Tjernberg, S. Hahne, C. Lilliehöök, L. Terenius, J. Thyberg and C. Nordstedt, *Journal of Biological Chemistry*, 1999, **274**, 12619–12625.
- 25 W. P. Esler, E. R. Stimson, J. R. Ghilardi, Y.-A. Lu, A. M. Felix, H. V. Vinters, P. W. Mantyh, J. P. Lee and J. E. Maggio, *Biochemistry*, 1996, **35**, 13914–13921.
- 26 Y. Sugimoto, Y. Kamada, Y. Tokunaga, H. Shinohara, M. Matsumoto, T. Kusakabe, T. Ohkuri and T. Ueda, *Biochemistry and Cell Biology*, 2011, **89**, 533–544.
- 27 S. C. Mansour, C. de la Fuente-Núñez and R. E. W. Hancock, *Journal of Peptide Science*, 2015, **21**, 323–329.
- 28 Y. Tokunaga, Y. Sakakibara, Y. Kamada, K. Watanabe and Y. Sugimoto, *Int J Biol Sci*, 2013, **9**, 219–227.
- 29 I. Kuznetsova, K. Turoverov and V. Uversky, *Int J Mol Sci*, 2014, **15**, 23090–23140.
- 30 I. Kuznetsova, B. Zaslavsky, L. Breydo, K. Turoverov and V. Uversky, *Molecules*, 2015, **20**, 1377–1409.
- 31 T. Bar and Y. Okon, <https://doi.org/10.1139/m93-011>, 2011, **39**, 81–86.
- 32 J. Lawrence, S.-H. Lee, A. Abdilla, M. D. Nothling, J. M. Ren, A. S. Knight, C. Fleischmann, Y. Li, A. S. Abrams, B. V. K. J. Schmidt, M. C. Hawker, L. A. Connal, A. J. McGrath, P. G. Clark, W. R. Gutekunst and C. J. Hawker, *J Am Chem Soc*, 2016, **138**, 6306–6310.
- 33 S. Perrier, *Macromolecules*, 2017, **50**, 7433–7447.
- 34 F. Piguet, H. Ouldali, F. Discala, M. F. Breton, J. C. Behrends, J. Pelta and A. Oukhaled, *Sci Rep*, DOI:10.1038/srep38675.
- 35 K. Devanand and J. C. Selser, *Asymptotic Behavior and Long-Range Interactions in Aqueous Solutions of Polyethylene oxide*, 1991, vol. 24.
- 36 C. E. Stauffer, *J Phys Chem*, 1965, **69**, 1933–1938.
- 37 F. Fischel-Ghodsian, L. Brown, E. Mathiowitz, D. Brandenburg and R. Langer, *Proceedings of the National Academy of Sciences*, 1988, **85**, 2403–2406.
- 38 A. Das, M. Shah and I. Saraogi, *ACS Bio & Med Chem Au*, 2022, **2**, 205–221.



- 39 D. Andersson, U. Carlsson and P.-O. Freskgård, *Eur J Biochem*, 2001, **268**, 1118–1128. [View Article Online](#)  
DOI:10.1039/D3TB02102E
- 40 J. Goldman and F. H. Carpenter, *Biochemistry*, 1974, **13**, 4566–4574.
- 41 O. M. Pena, N. Afacan, J. Pistolic, C. Chen, L. Madera, R. Falsafi, C. D. Fjell and R. E. W. Hancock, *PLoS One*, 2013, **8**, e52449.
- 42 H. Choe, A. S. Narayanan, D. A. Gandhi, A. Weinberg, R. E. Marcus, Z. Lee, R. A. Bonomo and E. M. Greenfield, *Clin Orthop Relat Res*, 2015, **473**, 2898–2907.
- 43 M. Wieczorek, H. Jenssen, J. Kindrachuk, W. R. P. Scott, M. Elliott, K. Hilpert, J. T. J. Cheng, R. E. W. Hancock and S. K. Straus, *Chem Biol*, 2010, **17**, 970–980.
- 44 E. F. Haney, B. (Catherine) Wu, K. Lee, A. L. Hilchie and R. E. W. Hancock, *Cell Chem Biol*, 2017, **24**, 969-980.e4.
- 45 D. E. Schlamadinger, J. E. Gable and J. E. Kim, *J Phys Chem B*, 2009, **113**, 14769–14778.
- 46 C. Mueller, M. A. H. Capelle, T. Arvinte, E. Seyrek and G. Borchard, *European Journal of Pharmaceutics and Biopharmaceutics*, 2011, **79**, 646–657.

